• Product nameAnti-Chk2 antibody
    See all Chk2 primary antibodies
  • Description
    Rabbit polyclonal to Chk2
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: all Mammals
  • Immunogen

    His-tagged 215 amino acid N-terminal of human chk2 fusion protein.

  • Positive control
    • HELA whole cell extract and 0.1ng of N-terminal his-tagged chk2 recombinant protein (see Figure 1)



Our Abpromise guarantee covers the use of ab477 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1500. Predicted molecular weight: 61 kDa.


  • FunctionRegulates cell cycle checkpoints and apoptosis in response to DNA damage, particularly to DNA double-strand breaks. Inhibits CDC25C phosphatase by phosphorylation on 'Ser-216', preventing the entry into mitosis. May also play a role in meiosis. Regulates the TP53 tumor suppressor through phosphorylation at 'Thr-18' and 'Ser-20'.
  • Tissue specificityHigh expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues.
  • Involvement in diseaseDefects in CHEK2 are associated with Li-Fraumeni syndrome 2 (LFS2) [MIM:609265]; a highly penetrant familial cancer phenotype usually associated with inherited mutations in p53/TP53.
    Defects in CHEK2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
    Defects in CHEK2 are found in some patients with osteogenic sarcoma (OSRC) [MIM:259500].
  • Sequence similaritiesBelongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CHK2 subfamily.
    Contains 1 FHA domain.
    Contains 1 protein kinase domain.
  • Post-translational
    Phosphorylated by PLK4.
  • Cellular localizationNucleus; Nucleus. Isoform 10 is present throughout the cell and Nucleus > PML body. Nucleus > nucleoplasm. Recruited into PML bodies together with TP53.
  • Information by UniProt
  • Database links
  • Alternative names
    • CDS 1 antibody
    • Cds1 antibody
    • Cds1 homolog antibody
    • Checkpoint kinase 2 antibody
    • Checkpoint like protein CHK2 antibody
    • CHEK 2 antibody
    • Chek2 antibody
    • Chk 2 antibody
    • CHK2 checkpoint homolog (S. pombe) antibody
    • CHK2 checkpoint homolog antibody
    • CHK2_HUMAN antibody
    • hCds1 antibody
    • HuCds 1 antibody
    • LFS 2 antibody
    • LFS2 antibody
    • PP1425 antibody
    • RAD 53 antibody
    • RAD53 antibody
    • Rad53 homolog antibody
    • Serine/threonine protein kinase Chk2 antibody
    • Serine/threonine-protein kinase Chk2 antibody
    see all

References for Anti-Chk2 antibody (ab477)

This product has been referenced in:
  • Fernet M  et al. Identification and functional consequences of a novel MRE11 mutation affecting 10 Saudi Arabian patients with the ataxia telangiectasia-like disorder. Hum Mol Genet 14:307-18 (2005). Read more (PubMed: 15574463) »
  • Fernet M  et al. Cellular responses to ionising radiation of AT heterozygotes: differences between missense and truncating mutation carriers. Br J Cancer 90:866-73 (2004). Read more (PubMed: 14970866) »

See all 3 Publications for this product

Product Wall

This antibody has never previously been reported to identify a 150 KD band, although it has identified others at 60KD-70 KD and lower band at 40-45 KD. Some suggestions/comments: - Are you using a different cellular type? Do your cells definitely ex...

Read More